TherapeuticsMD (TXMD) Misses Q3 EPS by $1.09

TherapeuticsMD (NASDAQ: TXMD) reported Q3 EPS of ($3.13), $1.09 worse than the analyst estimate of ($2.04). Revenue for the quarter came in at $20.9 million versus the consensus estimate of $30.2 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Prosensa Holding N.V. (RNA) Reports Q2 Loss of $1.18